Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474461 · ClinicalTrials.gov registry record · Phase 1
Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)
A Phase 1 study of Coronary Artery Disease and Congestive Heart Failure, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00474461: Completed Phase 1 study of Coronary Artery Disease and Congestive Heart Failure, sponsored by University of Louisville.
NCT00474461 is a Phase 1 study of Coronary Artery Disease and Congestive Heart Failure that has completed, run by University of Louisville. The registered enrollment target is 33 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474461, a Phase 1 study of Coronary Artery Disease and Congestive Heart Failure, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack. The central hypothesis is that CSCs infused into nonviable myocardial segments will regenerate infarcted myocardium by differentiating into cardiomyocytes and other cell types. According to our hypothesis, CSC infusion regenerates myocardium with consequent improvement in contractile function of the heart and general clinical status.
Conditions Studied
Interventions
- BIOLOGICAL Treatment group
Study Locations (1)
Kentucky
- Jewish Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
What the finished NCT00474461 record still lists
NCT00474461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Treatment group is the first listed.
NCT00474461 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00474461 about?
NCT00474461 is a clinical study titled "Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)". The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack. The central hypothesis is that CSCs infused into nonviable myocardial seg...
What is the current status of trial NCT00474461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2009-02. Estimated completion is 2013-09.
What conditions does trial NCT00474461 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Congestive Heart Failure.
What interventions are being tested in trial NCT00474461?
The interventions under investigation include: Treatment group (BIOLOGICAL).
Who is sponsoring clinical trial NCT00474461?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00474461 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00474461's enrollment target sits among peer trials
33 195th of 219 higher than 24 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
COMPLETED · Phase 1
-
Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
COMPLETED · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men
COMPLETED · Phase 1
-
Effect of Cocoa Flavanols on Vascular Function
COMPLETED · Phase 1
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia